Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36 clinical trials
featured
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK

crizotinib
lung cancer
lung carcinoma
  • 98 views
  • 23 Nov, 2020
  • 1 location
Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

Bioequivalence study to evaluate the pharmacokinetics of a new crizotinib encapsulated microsphere (eMS) formulation

  • 0 views
  • 29 Apr, 2021
  • 1 location
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective studies. Recently the FDA approved

  • 0 views
  • 07 Jun, 2021
  • 39 locations
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib

  • 0 views
  • 26 Jan, 2021
  • 30 locations
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China

serum bilirubin level
kinase inhibitor
cancer chemotherapy
KIT
kidney function test
  • 15 views
  • 11 Jun, 2021
  • 27 locations
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive

mycn protein
topotecan
thiotepa
isotretinoin
cyclophosphamide
  • 66 views
  • 03 Jun, 2021
  • 102 locations
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and

iobenguane
ganglioneuroblastoma
topotecan
cancer
tumor cells
  • 158 views
  • 02 Feb, 2021
  • 15 locations
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

squamous cell carcinoma
erlotinib
crizotinib
adenocarcinoma
metastasis
  • 1103 views
  • 24 Jun, 2021
  • 1135 locations
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes

crizotinib
measurable disease
squamous non-small cell lung cancer
cancer
ROS1
  • 0 views
  • 11 Apr, 2021
  • 1 location
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

This study is to allow access to crizotinib who were treated in previous Pfizer-sponsored studies in China.

  • 0 views
  • 28 Mar, 2021
  • 12 locations